With a median follow-up of 3.3 years, it was found that some of the CH-associated mutations (DNMT3A, TET2, and ASXL1) were persistent in 90 of 130 patients (68%) during remission, and their persistence was not associated with increased risk of relapse. Here, TET2 is linked to cyclic hematopoiesis.